GenMark Diagnostics Schedules First Quarter 2013 Financial Results Conference Call for May 8, 2013
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to
release its first quarter earnings results after market close on
Wednesday, May 8, 2013. Management will hold a conference call to review
the Company's first quarter performance starting at 4:15 p.m. (Eastern
Time) on the same day. The conference call will be concurrently webcast.
The link to the webcast will be available on the GenMark Diagnostics,
Inc. website at www.genmarkdx.com
under the investor relations section and will be archived for future
reference.
To listen to the conference call, please dial (877) 312-5847 (US/Canada)
or (253) 237-1154 (International) and use the conference ID number
"58727388" approximately five minutes prior to the start time.
About GenMark Diagnostics
GenMark Diagnostics is a leading provider of automated, multiplex
molecular diagnostic testing systems that detect and measure DNA and RNA
targets to diagnose disease and optimize patient treatment. Utilizing
GenMark's proprietary eSensor® detection technology, GenMark's eSensor
XT-8™ system is designed to support a broad range of molecular
diagnostic tests with a compact, easy-to-use workstation and
self-contained, disposable test cartridges. GenMark currently markets
four tests that are FDA cleared for IVD use: Cystic Fibrosis Genotyping
Test, Respiratory Viral Panel, Thrombophilia Risk Test, and Warfarin
Sensitivity Test. A number of other tests, including HCV Genotyping,
2C19 Genotyping, and 3A4/3A5 Genotyping are available for research use
only. For more information, visit www.genmarkdx.com.
